Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial
This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE)...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2022-04, Vol.63 (4), p.556-559 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 4 |
| container_start_page | 556 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 63 |
| creator | Chen, Hui Nan, Gang Wei, Ding Zhai, Ren-You Huang, Ming Yang, Wu-Wei Xing, Bao-Cai Zhu, Xu Xu, Hai-Feng Wang, Xiao-Dong Zhang, Xiao-Yong Zhu, Bao-Rang Liu, Peng Cao, Guang Gao, Song Hao, Chun-Yi Yang, Ren-Jie Guo, Jian-Hai Zhang, Xin Gao, Kun Wang, Kun Wang, Jian-Feng Li, Zi-Yu Zhu, Lin-Zhong Ding, Rong Li, Jing Zhao, Ling Shao, Yu-Jun Liu, Hai-Chun Xia, Jie-Lai Wang, Ling Kong, Ling-Min Chen, Zhi-Nan Bian, Huijie |
| description | This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 mo in the TACE + 131I-metuximab group (n = 160) and 3 mo in the TACE group (n = 160) (hazard ratio, 0.55; 95% CI, 0.43–0.70; P < 0.001). The median overall survival was 28 mo in the TACE + 131I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47–0.82; P = 0.001). Conclusion: TACE + 131I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients. |
| doi_str_mv | 10.2967/jnumed.121.262136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8973296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2651849127</sourcerecordid><originalsourceid>FETCH-LOGICAL-p244t-889fed13b8b4aae48dcdb3ecc7efce125ded61758af83b63ef57847d1b7cd8863</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EokvhB3CzxIUDWWI7_ggHpFUEdKUWOGzPkT8mrFeJHZyk0P4-fhhO2wuc5jAzz_vOOwi9JuWW1kK-P4VlALcllGypoISJJ2hDOOMFF0I-RZuSCFJwXvIz9GKaTmVZCqXUc3TGqkpyyvgG_bmAUc_e4l2aId3ifTiBnX0MOHaYMLIvrmBefvtBG9zEwfgADv_y8xEfkg6T1fMR8uLDutc9bo4wRBhM7P2dvgd1MeHrkGDKYG16wPeS0ULfL71OuNHJ-hAH_QHv8PcUp3F1cAP4awxZw8XB34F7h6-WPhuFsMo1vQ_eZrnDKvoSPet0P8Grx3qOrj9_OjQXxeW3L_tmd1mMtKrmQqm6A0eYUabSGirlrDMMrJXQWSCUO3CCSK50p5gRDDouVSUdMdI6pQQ7Rx8fuONicvCrl6T7dkw5nnTbRu3bfzvBH9sf8aZVtWT5Yxnw9hGQ4s8Fprkd_LQGoQPEZWopFzVTVX5lHn3z3-gpLink81oqOFFVTahkfwH5NqYT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2651849127</pqid></control><display><type>article</type><title>Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Chen, Hui ; Nan, Gang ; Wei, Ding ; Zhai, Ren-You ; Huang, Ming ; Yang, Wu-Wei ; Xing, Bao-Cai ; Zhu, Xu ; Xu, Hai-Feng ; Wang, Xiao-Dong ; Zhang, Xiao-Yong ; Zhu, Bao-Rang ; Liu, Peng ; Cao, Guang ; Gao, Song ; Hao, Chun-Yi ; Yang, Ren-Jie ; Guo, Jian-Hai ; Zhang, Xin ; Gao, Kun ; Wang, Kun ; Wang, Jian-Feng ; Li, Zi-Yu ; Zhu, Lin-Zhong ; Ding, Rong ; Li, Jing ; Zhao, Ling ; Shao, Yu-Jun ; Liu, Hai-Chun ; Xia, Jie-Lai ; Wang, Ling ; Kong, Ling-Min ; Chen, Zhi-Nan ; Bian, Huijie</creator><creatorcontrib>Chen, Hui ; Nan, Gang ; Wei, Ding ; Zhai, Ren-You ; Huang, Ming ; Yang, Wu-Wei ; Xing, Bao-Cai ; Zhu, Xu ; Xu, Hai-Feng ; Wang, Xiao-Dong ; Zhang, Xiao-Yong ; Zhu, Bao-Rang ; Liu, Peng ; Cao, Guang ; Gao, Song ; Hao, Chun-Yi ; Yang, Ren-Jie ; Guo, Jian-Hai ; Zhang, Xin ; Gao, Kun ; Wang, Kun ; Wang, Jian-Feng ; Li, Zi-Yu ; Zhu, Lin-Zhong ; Ding, Rong ; Li, Jing ; Zhao, Ling ; Shao, Yu-Jun ; Liu, Hai-Chun ; Xia, Jie-Lai ; Wang, Ling ; Kong, Ling-Min ; Chen, Zhi-Nan ; Bian, Huijie</creatorcontrib><description>This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 mo in the TACE + 131I-metuximab group (n = 160) and 3 mo in the TACE group (n = 160) (hazard ratio, 0.55; 95% CI, 0.43–0.70; P < 0.001). The median overall survival was 28 mo in the TACE + 131I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47–0.82; P = 0.001). Conclusion: TACE + 131I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.121.262136</identifier><identifier>PMID: 34475235</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Brief Communication ; Chemoembolization ; Clinical trials ; Hepatic artery ; Hepatocellular carcinoma ; Liver cancer ; Patients ; Safety ; Survival ; Tumors</subject><ispartof>The Journal of nuclear medicine (1978), 2022-04, Vol.63 (4), p.556-559</ispartof><rights>Copyright Society of Nuclear Medicine Apr 1, 2022</rights><rights>2022 by the Society of Nuclear Medicine and Molecular Imaging. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>Nan, Gang</creatorcontrib><creatorcontrib>Wei, Ding</creatorcontrib><creatorcontrib>Zhai, Ren-You</creatorcontrib><creatorcontrib>Huang, Ming</creatorcontrib><creatorcontrib>Yang, Wu-Wei</creatorcontrib><creatorcontrib>Xing, Bao-Cai</creatorcontrib><creatorcontrib>Zhu, Xu</creatorcontrib><creatorcontrib>Xu, Hai-Feng</creatorcontrib><creatorcontrib>Wang, Xiao-Dong</creatorcontrib><creatorcontrib>Zhang, Xiao-Yong</creatorcontrib><creatorcontrib>Zhu, Bao-Rang</creatorcontrib><creatorcontrib>Liu, Peng</creatorcontrib><creatorcontrib>Cao, Guang</creatorcontrib><creatorcontrib>Gao, Song</creatorcontrib><creatorcontrib>Hao, Chun-Yi</creatorcontrib><creatorcontrib>Yang, Ren-Jie</creatorcontrib><creatorcontrib>Guo, Jian-Hai</creatorcontrib><creatorcontrib>Zhang, Xin</creatorcontrib><creatorcontrib>Gao, Kun</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><creatorcontrib>Wang, Jian-Feng</creatorcontrib><creatorcontrib>Li, Zi-Yu</creatorcontrib><creatorcontrib>Zhu, Lin-Zhong</creatorcontrib><creatorcontrib>Ding, Rong</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Zhao, Ling</creatorcontrib><creatorcontrib>Shao, Yu-Jun</creatorcontrib><creatorcontrib>Liu, Hai-Chun</creatorcontrib><creatorcontrib>Xia, Jie-Lai</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Kong, Ling-Min</creatorcontrib><creatorcontrib>Chen, Zhi-Nan</creatorcontrib><creatorcontrib>Bian, Huijie</creatorcontrib><title>Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial</title><title>The Journal of nuclear medicine (1978)</title><description>This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 mo in the TACE + 131I-metuximab group (n = 160) and 3 mo in the TACE group (n = 160) (hazard ratio, 0.55; 95% CI, 0.43–0.70; P < 0.001). The median overall survival was 28 mo in the TACE + 131I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47–0.82; P = 0.001). Conclusion: TACE + 131I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.</description><subject>Brief Communication</subject><subject>Chemoembolization</subject><subject>Clinical trials</subject><subject>Hepatic artery</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Patients</subject><subject>Safety</subject><subject>Survival</subject><subject>Tumors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkU1v1DAQhi0EokvhB3CzxIUDWWI7_ggHpFUEdKUWOGzPkT8mrFeJHZyk0P4-fhhO2wuc5jAzz_vOOwi9JuWW1kK-P4VlALcllGypoISJJ2hDOOMFF0I-RZuSCFJwXvIz9GKaTmVZCqXUc3TGqkpyyvgG_bmAUc_e4l2aId3ifTiBnX0MOHaYMLIvrmBefvtBG9zEwfgADv_y8xEfkg6T1fMR8uLDutc9bo4wRBhM7P2dvgd1MeHrkGDKYG16wPeS0ULfL71OuNHJ-hAH_QHv8PcUp3F1cAP4awxZw8XB34F7h6-WPhuFsMo1vQ_eZrnDKvoSPet0P8Grx3qOrj9_OjQXxeW3L_tmd1mMtKrmQqm6A0eYUabSGirlrDMMrJXQWSCUO3CCSK50p5gRDDouVSUdMdI6pQQ7Rx8fuONicvCrl6T7dkw5nnTbRu3bfzvBH9sf8aZVtWT5Yxnw9hGQ4s8Fprkd_LQGoQPEZWopFzVTVX5lHn3z3-gpLink81oqOFFVTahkfwH5NqYT</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Chen, Hui</creator><creator>Nan, Gang</creator><creator>Wei, Ding</creator><creator>Zhai, Ren-You</creator><creator>Huang, Ming</creator><creator>Yang, Wu-Wei</creator><creator>Xing, Bao-Cai</creator><creator>Zhu, Xu</creator><creator>Xu, Hai-Feng</creator><creator>Wang, Xiao-Dong</creator><creator>Zhang, Xiao-Yong</creator><creator>Zhu, Bao-Rang</creator><creator>Liu, Peng</creator><creator>Cao, Guang</creator><creator>Gao, Song</creator><creator>Hao, Chun-Yi</creator><creator>Yang, Ren-Jie</creator><creator>Guo, Jian-Hai</creator><creator>Zhang, Xin</creator><creator>Gao, Kun</creator><creator>Wang, Kun</creator><creator>Wang, Jian-Feng</creator><creator>Li, Zi-Yu</creator><creator>Zhu, Lin-Zhong</creator><creator>Ding, Rong</creator><creator>Li, Jing</creator><creator>Zhao, Ling</creator><creator>Shao, Yu-Jun</creator><creator>Liu, Hai-Chun</creator><creator>Xia, Jie-Lai</creator><creator>Wang, Ling</creator><creator>Kong, Ling-Min</creator><creator>Chen, Zhi-Nan</creator><creator>Bian, Huijie</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220401</creationdate><title>Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial</title><author>Chen, Hui ; Nan, Gang ; Wei, Ding ; Zhai, Ren-You ; Huang, Ming ; Yang, Wu-Wei ; Xing, Bao-Cai ; Zhu, Xu ; Xu, Hai-Feng ; Wang, Xiao-Dong ; Zhang, Xiao-Yong ; Zhu, Bao-Rang ; Liu, Peng ; Cao, Guang ; Gao, Song ; Hao, Chun-Yi ; Yang, Ren-Jie ; Guo, Jian-Hai ; Zhang, Xin ; Gao, Kun ; Wang, Kun ; Wang, Jian-Feng ; Li, Zi-Yu ; Zhu, Lin-Zhong ; Ding, Rong ; Li, Jing ; Zhao, Ling ; Shao, Yu-Jun ; Liu, Hai-Chun ; Xia, Jie-Lai ; Wang, Ling ; Kong, Ling-Min ; Chen, Zhi-Nan ; Bian, Huijie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p244t-889fed13b8b4aae48dcdb3ecc7efce125ded61758af83b63ef57847d1b7cd8863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brief Communication</topic><topic>Chemoembolization</topic><topic>Clinical trials</topic><topic>Hepatic artery</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Patients</topic><topic>Safety</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>Nan, Gang</creatorcontrib><creatorcontrib>Wei, Ding</creatorcontrib><creatorcontrib>Zhai, Ren-You</creatorcontrib><creatorcontrib>Huang, Ming</creatorcontrib><creatorcontrib>Yang, Wu-Wei</creatorcontrib><creatorcontrib>Xing, Bao-Cai</creatorcontrib><creatorcontrib>Zhu, Xu</creatorcontrib><creatorcontrib>Xu, Hai-Feng</creatorcontrib><creatorcontrib>Wang, Xiao-Dong</creatorcontrib><creatorcontrib>Zhang, Xiao-Yong</creatorcontrib><creatorcontrib>Zhu, Bao-Rang</creatorcontrib><creatorcontrib>Liu, Peng</creatorcontrib><creatorcontrib>Cao, Guang</creatorcontrib><creatorcontrib>Gao, Song</creatorcontrib><creatorcontrib>Hao, Chun-Yi</creatorcontrib><creatorcontrib>Yang, Ren-Jie</creatorcontrib><creatorcontrib>Guo, Jian-Hai</creatorcontrib><creatorcontrib>Zhang, Xin</creatorcontrib><creatorcontrib>Gao, Kun</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><creatorcontrib>Wang, Jian-Feng</creatorcontrib><creatorcontrib>Li, Zi-Yu</creatorcontrib><creatorcontrib>Zhu, Lin-Zhong</creatorcontrib><creatorcontrib>Ding, Rong</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Zhao, Ling</creatorcontrib><creatorcontrib>Shao, Yu-Jun</creatorcontrib><creatorcontrib>Liu, Hai-Chun</creatorcontrib><creatorcontrib>Xia, Jie-Lai</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Kong, Ling-Min</creatorcontrib><creatorcontrib>Chen, Zhi-Nan</creatorcontrib><creatorcontrib>Bian, Huijie</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Hui</au><au>Nan, Gang</au><au>Wei, Ding</au><au>Zhai, Ren-You</au><au>Huang, Ming</au><au>Yang, Wu-Wei</au><au>Xing, Bao-Cai</au><au>Zhu, Xu</au><au>Xu, Hai-Feng</au><au>Wang, Xiao-Dong</au><au>Zhang, Xiao-Yong</au><au>Zhu, Bao-Rang</au><au>Liu, Peng</au><au>Cao, Guang</au><au>Gao, Song</au><au>Hao, Chun-Yi</au><au>Yang, Ren-Jie</au><au>Guo, Jian-Hai</au><au>Zhang, Xin</au><au>Gao, Kun</au><au>Wang, Kun</au><au>Wang, Jian-Feng</au><au>Li, Zi-Yu</au><au>Zhu, Lin-Zhong</au><au>Ding, Rong</au><au>Li, Jing</au><au>Zhao, Ling</au><au>Shao, Yu-Jun</au><au>Liu, Hai-Chun</au><au>Xia, Jie-Lai</au><au>Wang, Ling</au><au>Kong, Ling-Min</au><au>Chen, Zhi-Nan</au><au>Bian, Huijie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2022-04-01</date><risdate>2022</risdate><volume>63</volume><issue>4</issue><spage>556</spage><epage>559</epage><pages>556-559</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 mo in the TACE + 131I-metuximab group (n = 160) and 3 mo in the TACE group (n = 160) (hazard ratio, 0.55; 95% CI, 0.43–0.70; P < 0.001). The median overall survival was 28 mo in the TACE + 131I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47–0.82; P = 0.001). Conclusion: TACE + 131I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub><pmid>34475235</pmid><doi>10.2967/jnumed.121.262136</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2022-04, Vol.63 (4), p.556-559 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8973296 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Brief Communication Chemoembolization Clinical trials Hepatic artery Hepatocellular carcinoma Liver cancer Patients Safety Survival Tumors |
| title | Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A32%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%20Artery%20Injection%20of%20131I-Metuximab%20Combined%20with%20Transcatheter%20Arterial%20Chemoembolization%20for%20Unresectable%20Hepatocellular%20Carcinoma:%20A%20Prospective%20Nonrandomized,%20Multicenter%20Clinical%20Trial&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Chen,%20Hui&rft.date=2022-04-01&rft.volume=63&rft.issue=4&rft.spage=556&rft.epage=559&rft.pages=556-559&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.121.262136&rft_dat=%3Cproquest_pubme%3E2651849127%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2651849127&rft_id=info:pmid/34475235&rfr_iscdi=true |